Testing Laboratories NAICS 541380

May 30, 2026 - The Value of Animal Testing in Labs Increasingly Questioned

• Critics of the use of animals in the testing labs industry stem not only from cruelty concerns but from challenges with oversight, transparency, and scientific reliability. According to the Humane Society of the United States, an estimated 100 million animals are used in experiments worldwide each year. Opponents also question the predictive value of animal models: the US Food and Drug Administration (FDA) has reported that roughly 90% of drugs that enter human clinical trials ultimately fail to gain approval, despite showing promise in preclinical testing. These concerns have fueled growing interest in alternatives such as organ-on-chip systems, advanced cell cultures, and computational models. In response, agencies including the FDA and the National Institutes of Health have increased investment in human-relevant research methods that could reduce reliance on animal testing while potentially improving the ability to predict human outcomes.
• The non-medical testing laboratory industry is consolidating fast and modernizing faster as the sector is being reshaped by aggressive M&A activity by its top players. Industry giants and private equity firms are snapping up accredited labs with recurring, regulation-driven revenue. (Eurofins alone has made 378 acquisitions since 2015). Driving underlying growth are tightening environmental rules around PFAS (forever chemicals), surging demand for food and materials testing, and rapid adoption of AI, automation, and IoT tools. External pressure is also affecting the industry, with tariffs on imported testing equipment squeezing margins. But the bigger story is structural: a highly fragmented industry is being rolled up by players racing to offer clients single-source, globally accredited testing at scale.

• Researchers at MIT and the University of Toronto recently put 19 top AI models to the test with the LabSafety Bench framework, challenging them on lab hazard identification, risk assessment, and experimental decision-making across biology, chemistry, physics, and other testing scenarios. The results were sobering: no model scored above 70%, and many stumbled below 50% on high-risk tasks like handling radiation, cryogenics, and complex equipment. Even more concerning, the AIs often gave confident but dangerously wrong guidance, a stark reminder that they can “hallucinate” in real-world lab settings. For the testing laboratory industry, this signals that while AI can assist, it is far from ready to run experiments or make safety calls on its own. Labs need rigorous human oversight, strict validation, and robust governance to keep AI on the side of support rather than risk.
• With the EPA delaying comprehensive federal regulation of PFAS (“forever chemicals”), individual states are increasingly stepping in to manage environmental risks. These persistent, non-degrading chemicals are turning up in biosolids spread on farmland, raising concerns about soil, water, and agricultural contamination. States face challenges of limited funding, technical capacity gaps, and reliance on paused EPA commitments. For environmental consultants, this patchwork of state-level standards creates both risk and opportunity: risk in inconsistent regulation and remediation liability, but opportunity in helping states develop monitoring programs, risk assessments, and mitigation strategies. Maine’s aggressive approach (banning biosolids, mandating testing, and funding remediation) serves as a potential model. Meanwhile, other states must navigate diverse regulatory regimes while planning for future PFAS cleanup.